Zomedica Corp. [AMEX: ZOM] plunged by $0.0 during the normal trading session on Tuesday and reaching a high of $0.20 during the day while it closed the day at $0.20. The company report on November 14, 2022 that Zomedica Announces Third Quarter 2022 Financial Results: $4.78 Million Revenue; 75% Gross Margin & $158.49 Million in Cash, Cash Equivalents, and Available-For-Sale Securities.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”, a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, reported consolidated financial results for the three- and nine-month periods ended September 30, 2022. Amounts are presented under accounting principles generally accepted in the United States of America (“U.S. GAAP”).
Larry Heaton, Zomedica’s Chief Executive Officer, commented: “During the third quarter of 2022 we both grew revenue organically, and also closed on several acquisitions. We were pleased with our revenue growth to $4.78 million, which reflects an approximate 24% increase in the sales of our pre-existing PulseVet® and TRUFORMA® products over 2021 levels; and a 17% increase, on a pro-forma basis, over the combined revenue of Zomedica, Pulse Veterinary Technologies (“PulseVet”), and Assisi Animal Health (“Assisi”) as standalone companies, of $4.10 million from the same period in 2021.
Zomedica Corp. stock has also gained 0.72% of its value over the past 7 days. However, ZOM stock has declined by -14.65% in the 3 months of the year. Over the past six months meanwhile, it has lost -10.36% and lost -35.92% year-on date.
The market cap for ZOM stock reached $189.47 million, with 979.95 million shares outstanding and 965.42 million shares in the current float. Compared to the average trading volume of 6.43M shares, ZOM reached a trading volume of 6248632 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Zomedica Corp. [ZOM]:
The Average True Range (ATR) for Zomedica Corp. is set at 0.01, with the Price to Sales ratio for ZOM stock in the period of the last 12 months amounting to 11.21. The Price to Book ratio for the last quarter was 0.73, with the Price to Cash per share for the same quarter was set at 0.12.
ZOM stock trade performance evaluation
Zomedica Corp. [ZOM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.72. With this latest performance, ZOM shares dropped by -18.13% in over the last four-week period, additionally sinking by -10.36% over the last 6 months – not to mention a drop of -45.85% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZOM stock in for the last two-week period is set at 41.74, with the RSI for the last a single of trading hit 42.57, and the three-weeks RSI is set at 42.40 for Zomedica Corp. [ZOM]. The present Moving Average for the last 50 days of trading for this stock 0.2133, while it was recorded at 0.1927 for the last single week of trading, and 0.2562 for the last 200 days.
Zomedica Corp. [ZOM]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Zomedica Corp. [ZOM] shares currently have an operating margin of -517.14 and a Gross Margin at +46.32. Zomedica Corp.’s Net Margin is presently recorded at -444.78.
Return on Equity for this stock declined to -11.01, with Return on Assets sitting at -10.61.
Zomedica Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 17.50 and a Current Ratio set at 17.80.
Zomedica Corp. [ZOM]: Insider Ownership positions
There are presently around $18 million, or 9.70% of ZOM stock, in the hands of institutional investors. The top three institutional holders of ZOM stocks are: VANGUARD GROUP INC with ownership of 46,329,005, which is approximately 5.111% of the company’s market cap and around 1.48% of the total institutional ownership; BLACKROCK INC., holding 11,320,780 shares of the stock with an approximate value of $2.22 million in ZOM stocks shares; and CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC., currently with $2.19 million in ZOM stock with ownership of nearly 0.179% of the company’s market capitalization.
Positions in Zomedica Corp. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 25 institutional holders increased their position in Zomedica Corp. [AMEX:ZOM] by around 3,349,305 shares. Additionally, 34 investors decreased positions by around 5,531,699 shares, while 42 investors held positions by with 83,513,606 shares. The mentioned changes placed institutional holdings at 92,394,610 shares, according to the latest SEC report filing. ZOM stock had 9 new institutional investments in for a total of 500,622 shares, while 16 institutional investors sold positions of 1,776,674 shares during the same period.